Josef Messinger

Summary

Affiliation: Solvay Pharmaceuticals
Country: The Netherlands

Publications

  1. ncbi New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1
    Josef Messinger
    Solvay Pharmaceuticals Research Laboratories, Hannover, Germany
    Mol Cell Endocrinol 248:192-8. 2006
  2. ncbi Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
    Josef Messinger
    Solvay Pharmaceuticals Research Laboratories, Hans Böckler Allee 20, D 30173 Hannover, Germany
    Mol Cell Endocrinol 301:216-24. 2009
  3. ncbi Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts
    Bettina Husen
    Solvay Pharmaceuticals Research Laboratories, Hans Böckler Allee 20, 30173 Hannover, Germany
    Endocrinology 147:5333-9. 2006
  4. ncbi Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent disease
    Martin Frotscher
    8 2 Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrucken, Germany
    J Med Chem 51:2158-69. 2008
  5. ncbi Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics
    Sandrine Marchais-Oberwinkler
    8 2 Pharmaceutical and Medicinal Chemistry, Saarland University, PO Box 15 11 50, D 66041 Saarbrucken, Germany
    J Med Chem 51:4685-98. 2008

Collaborators

  • Bettina Husen
  • Rolf W Hartmann
  • Umadevi Bhoga
  • Martin Frotscher
  • Sandrine Marchais-Oberwinkler
  • Hubert Thole
  • Alexander Neugebauer
  • Patricia Kruchten
  • Erika Ziegler
  • Ursula Müller-Vieira
  • Christiane Scherer
  • Ludivine Fetzer
  • Emmanuel Bey

Detail Information

Publications5

  1. ncbi New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1
    Josef Messinger
    Solvay Pharmaceuticals Research Laboratories, Hannover, Germany
    Mol Cell Endocrinol 248:192-8. 2006
    ..Furthermore, the pyrimidinone proved its use in vivo by significantly reducing 17betaHSD1-dependent tumor growth in a new nude mouse model...
  2. ncbi Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
    Josef Messinger
    Solvay Pharmaceuticals Research Laboratories, Hans Böckler Allee 20, D 30173 Hannover, Germany
    Mol Cell Endocrinol 301:216-24. 2009
    ..In conclusion, estrone C15 derivative compound 21 can be regarded as a promising lead compound for further development as a 17beta-HSD1 inhibitor...
  3. ncbi Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts
    Bettina Husen
    Solvay Pharmaceuticals Research Laboratories, Hans Böckler Allee 20, 30173 Hannover, Germany
    Endocrinology 147:5333-9. 2006
    ..The results evidently show that estrogenic response for E1 is enhanced by the local action of HSD17B1 in vivo, and thus, the enzyme is a potential target for pharmacological inhibition of estrogen action...
  4. ncbi Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent disease
    Martin Frotscher
    8 2 Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrucken, Germany
    J Med Chem 51:2158-69. 2008
    ....
  5. ncbi Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics
    Sandrine Marchais-Oberwinkler
    8 2 Pharmaceutical and Medicinal Chemistry, Saarland University, PO Box 15 11 50, D 66041 Saarbrucken, Germany
    J Med Chem 51:4685-98. 2008
    ..The 1-phenyl compound 32 showed a very high inhibitory activity for 17beta-HSD1 (IC50 = 20 nM) and good selectivity (17beta-HSD2 and ERs) and pharmacokinetic properties after peroral application...